Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Arbutus Biopharma (NASDAQ: ABUS) Announces $230 Million Dutch Auction Tender Offer

Arbutus Biopharma Corporation (NASDAQ: ABUS) announced a modified Dutch auction tender offer to buy back as much as $230 million in common stock at a price range of $5.00 to $5.75 per share.

Nitish Kishor | 24 August 2026

Iovance Biotherapeutics (NASDAQ: IOVA) Falls 8% Despite Raised UBS Price Target

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) shares closed down 8% at $8.29 after UBS adjusted its price target to $7 from $4, while reaffirming a Neutral rating.

Nitish Kishor | 24 August 2026

Gossamer Bio (NASDAQ: GOSS) Finalizes Up to $250 Million Financing Tied to Seralutinib

Gossamer Bio, Inc. (NASDAQ: GOSS) finalized a private placement financing agreement for as much as $250 million linked to seralutinib development, featuring a $25 million upfront payment and $125 million contingent on FDA acceptance of the PAH NDA.

Nitish Kishor | 24 August 2026

Jupiter Neurosciences (NASDAQ: JUNS) Rises 21% on PharmAla MDMA Licensing Deal

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) shares closed up 21% at $6.28 after the company priced a $2.0 million registered direct offering of 307,692 shares, adding modest near-term capital.

Nitish Kishor | 24 August 2026

Jupiter Neurosciences (NASDAQ: JUNS) Secures Exclusive U.S. Rights to PharmAla's ALA-002

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) secured exclusive U.S. rights to PharmAla's patented non-racemic MDMA formulation ALA-002, giving Jupiter a psychedelic neuropsychiatric asset.

Nitish Kishor | 24 August 2026

Arcturus Therapeutics (NASDAQ: ARCT) Rises 22% on Cash Runway and Upcoming Catalysts

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares closed up 22% at $13.45 after the company reported a widened Q2 net loss of $23.8 million as collaboration revenue declined following reduced recognition from CSL Seqirus.

Nitish Kishor | 24 August 2026

Werewolf Therapeutics (NASDAQ: HOWL) to Merge With Ambros Therapeutics in All-Stock Deal

Werewolf Therapeutics, Inc. (NASDAQ: HOWL) will merge with Ambros Therapeutics in an all-stock transaction to form Nasdaq-listed Ambros Therapeutics, shifting focus to neridronate for CRPS-1.

Nitish Kishor | 24 August 2026

Bessent's Iran D-Day as Gold Hits a 3-Month High, Alibaba Slumps, US-Canada Tariffs Bite, and Chips Sell Off: 7 Reads Before Monday's Bell

1. IRAN/MARKETS: Bessent to Unveil "Greatest Financial Offensive Ever Marshaled" Against Iran; Gold Hits a Three-Month High as Oil and Yields Ease

Nitish Kishor | 24 August 2026

Two Tobacco Rivals Just Found a New Reason to Work Together

Philip Morris International (NYSE:PM) announced that, through its non-US affiliates, it has entered into a contract manufacturing arrangement for combustible cigarettes with Philip Morris USA, an operating company of Altria (NYSE:MO). Altria separately confirmed the arrangement, describing it as intended to enhance the efficiency …

Nitish Kishor | 24 August 2026

Why Is Vanda Pharmaceuticals (NASDAQ:VNDA) Rising Pre-Market Today?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares ticked higher in pre-market trading after the company announced that its investigational drug imsidolimab received Orphan Designation from the European Commission for the treatment of Generalized Pustular Psoriasis, a severe and potentially life-threatening inflammatory skin disease. The designation marks …

Nitish Kishor | 24 August 2026
Support

Hi! How can we help you today?

Loading…